Sign In
Buy BTAI
$1.26
-0.0400 (-3.08%)
At Close: Jun 23, 2026
BioXcel Therapeutics, Inc. (BTAI) Q3 2022 Earnings Call Transcript
03:22pm, Thursday, 10'th Nov 2022
BioXcel Therapeutics, Inc. (NASDAQ:BTAI ) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET Company Participants Vimal Mehta - Chief Executive Officer & Founder Matt Wiley - Chief Commerci
BioXcel Therapeutics to Report Third Quarter 2022 Financial Results on November 10, 2022
07:00am, Thursday, 27'th Oct 2022
NEW HAVEN, Conn., Oct. 27, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medici
BioXcel Therapeutics to Participate at the H.C. Wainwright 24th Annual Global Investment Conference
07:00am, Wednesday, 07'th Sep 2022
NEW HAVEN, Conn., Sept. 07, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medic
BioXcel Therapeutics, Inc. (BTAI) CEO Vimal Mehta on Q2 2022 Results - Earnings Call Transcript
12:18pm, Tuesday, 09'th Aug 2022
BioXcel Therapeutics, Inc. (NASDAQ:BTAI ) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET Company Participants Vimal Mehta - Chief Executive Officer & Founder Richard Steinhart - Senior Vic
BioXcel Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022
07:00am, Tuesday, 26'th Jul 2022
NEW HAVEN, Conn., July 26, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop tran
BioXcel Therapeutics: BXCL501 For Acute Agitation In Patients With Dementia And Alzheimer's - A Great Asset
05:02am, Tuesday, 19'th Jul 2022
BioXcel is currently conducting phase II and III trials of BXCL501 to treat acute agitation in patients with dementia and Alzheimer's. The results of phase II are expected very soon (July or August),
1 Beaten-Down Stock That Could Soar
02:30pm, Saturday, 16'th Jul 2022 The Motley Fool
Will this biotech's recent rebound last?
1 Beaten-Down Stock That Could Soar
10:30am, Saturday, 16'th Jul 2022
Will this biotech's recent rebound last?
Twitter Shares Surge Around 8%, Here's 66 Biggest Movers From Yesterday
09:58am, Thursday, 14'th Jul 2022 Benzinga
Gainers
Qurate Retail, Inc. (NASDAQ: QRTEB) shares climbed 71.1% to close at $5.20. Qurate Retail will host a conference call to discuss Q2 results on Friday, August 5th.
Liberty TripAdvisor Holdings
Why BioXcel Therapeutics Was a Winner This Week
09:57pm, Friday, 08'th Jul 2022 The Motley Fool
The stock is tagged as a buy by an investment bank initiating coverage.
Why BioXcel Therapeutics Was a Winner This Week
05:57pm, Friday, 08'th Jul 2022
The stock is tagged as a buy by an investment bank initiating coverage.
Benzinga's Top Ratings Upgrades, Downgrades For July 7, 2022
02:04pm, Thursday, 07'th Jul 2022 Benzinga
Upgrades
For Pacific Premier Bancorp Inc (NASDAQ:PPBI), Raymond James upgraded the previous rating of Outperform to Strong Buy. In the first quarter, Pacific Premier Bancorp showed an EPS of $0.70, co
BioXcel Therapeutics Appoints Michael P. Miller to Board of Directors
11:00am, Tuesday, 05'th Jul 2022 GlobeNewswire Inc.
NEW HAVEN, Conn., July 05, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop tr
BioXcel Therapeutics to Participate at Two Upcoming Investor Conferences
07:00am, Tuesday, 07'th Jun 2022
NEW HAVEN, Conn., June 07, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop tran
2 Stocks Under $20 That Could Double Your Money
03:15pm, Friday, 27'th May 2022 The Motley Fool
These two companies have gotten quite the haircuts in recent months.
